Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
Developing a metabolite biomarker model for nephropathy in T1D patients
Despite appropriate treatment, diabetic nephropathy (DN) remains a major complication in diabetic patients and is the leading cause of end- stage renal disease. This unfavorable result is most likely due to the lack of efficient early detection method and the poor understanding of the pathogenic mechanisms of DN. Solving these two problems rely heavily on the extensive and systematic study of biomarkers for DN. Metabolome, the collection of all metabolites, is the closest to phenotype and metabolomics is a more direct way to study the effect of disease on human body since a subtle change at mRNA or protein level may lead to drastic alternations of the metabolites. This technique is becoming increasingly popular to study complex disease mechanisms with the aim to identify metabolites that are novel outcome or mechanistic biomarkers. In our proof-of-concept study, I have profiled urine samples from 40 T1D nephropathy patients and 40 matched T1D patients without any complication using liquid chromatography-mass spectrometry (LC-MS). The multivariate analysis results showed very good separation of the two groups, indicating the efficacy of the metabolite panel in disease classification. Based on these exciting results, we propose to further profile additional 160 urine samples using comphrehensive LC-MS technique and generate corrsponding metabolites candidates panel. These metabolite candidates will be further identified by MS and their multiple reaction monitoring (MRM) transitions developed and optimized. This metabolite panel will then be analyzed in another 440 urine samples using quantitative MRM-MS assay to confirm its performance. Extensive multivariate analysis and network-based function analysis will then be used to establish the metabolite panel/mode, which will be further evaluated using known samples and then used to predict the risk of DN in T1D patients. Our main goal is to establish an efficient metabolite biomarker panel that will provide sensitive and accurate prediction and new insights in understanding the mechanism of DN. These results will provide critical information for the next stage of clinical application of this biomarker panel and hence greatly hasten the biomarker development for DN.
Drag a column header and drop it here to group by that column
Developing a metabolite biomarker model for nephropathy in T1D patients (Zhi, Wenbo)
View Progress Report Document
No uploaded documents found.
Year: 2018; Items: 1
Proteins of TNF-a and IL6 Pathways Are Elevated in Serum of Type-1 Diabetes Patients with Microalbuminuria.
Purohit S, Sharma A, Zhi W, Bai S, Hopkins D, Steed L, Bode B, Anderson SW, Reed JC, Steed RD, She JX
Frontiers in immunology
, 2018 (9), 154
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Nephropathy Committee has the principal function of furthering the mission of the consortium with regard to diabetic kidney disease.
Curation Flag Information
New comment to be added:
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!